MAFLD vs NAFLD: Where are we?
- 1 October 2021
- journal article
- letter
- Published by Elsevier in Digestive and Liver Disease
- Vol. 53 (10) , 1368-1372
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- MAFLD and risk of CKDMetabolism, 2021
- FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)Journal of Hepatology, 2021
- Redefining fatty liver disease: an international patient perspectiveThe Lancet Gastroenterology & Hepatology, 2021
- MAFLD identifies patients with significant hepatic fibrosis better than NAFLDLiver International, 2020
- The NAFLD‐MAFLD debate: Eminence vs evidenceLiver International, 2020
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementJournal of Hepatology, 2020
- Comparison of MAFLD and NAFLD diagnostic criteria in real worldLiver International, 2020
- MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver DiseaseGastroenterology, 2020
- NAFLD in children: new genes, new diagnostic modalities and new drugsNature Reviews Gastroenterology & Hepatology, 2019
- AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directionsDigestive and Liver Disease, 2017